|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.31 USD | -3.37% |
|
-16.54% | -45.53% |
| 23/05 | Transcript : Scholar Rock Holding Corporation Presents at UBS Obesity Therapeutics Day, May-23-2024 09:00 AM | |
| 22/05 | Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity | MT |
Scholar Rock Holding Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 33.19 million compared to USD 18.82 million a year ago. Net loss was USD 134.5 million compared to USD 131.8 million a year ago.
Basic loss per share from continuing operations was USD 2.26 compared to USD 3.59 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -45.53% | 85Cr | |
| +9.81% | 12TCr | |
| +9.99% | 11TCr | |
| -11.75% | 2.34TCr | |
| -1.69% | 2.21TCr | |
| -10.23% | 1.83TCr | |
| -41.92% | 1.66TCr | |
| -15.81% | 1.6TCr | |
| +6.17% | 1.4TCr | |
| +14.80% | 1.17TCr |
SCHOLAR ROCK HOLDING CORPORATION 
